New targets for resistant prostate cancer

Oncotarget. 2014 Oct 15;5(19):8816-7. doi: 10.18632/oncotarget.2544.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Androgen Receptor Antagonists / therapeutic use*
  • Androstenes / therapeutic use
  • Benzamides
  • Humans
  • Male
  • Nitriles
  • Phenylthiohydantoin / analogs & derivatives
  • Phenylthiohydantoin / therapeutic use
  • Phosphatidylinositol 3-Kinases / genetics
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Prostatic Neoplasms, Castration-Resistant / genetics
  • Proto-Oncogene Proteins c-akt / genetics
  • Proto-Oncogene Proteins c-myb / biosynthesis
  • Proto-Oncogene Proteins c-myb / genetics
  • Receptors, Androgen / genetics*
  • Receptors, Androgen / metabolism
  • Receptors, Glucocorticoid / biosynthesis
  • Receptors, Glucocorticoid / genetics
  • Signal Transduction
  • Wnt Proteins / genetics
  • beta Catenin / genetics

Substances

  • Androgen Receptor Antagonists
  • Androstenes
  • Benzamides
  • CTNNB1 protein, human
  • Nitriles
  • Proto-Oncogene Proteins c-myb
  • Receptors, Androgen
  • Receptors, Glucocorticoid
  • Wnt Proteins
  • beta Catenin
  • Phenylthiohydantoin
  • enzalutamide
  • Proto-Oncogene Proteins c-akt
  • abiraterone